Abstract
Heat shock protein–90 (Hsp90) is a molecular chaperone critical to the folding, stability and activity of over 200 client proteins including many responsible for tumor initiation, progression and metastasis. Hsp90 chaperone function is linked to its ATPase activity and Hsp90 inhibitors interfere with this activity, thereby making Hsp90 an attractive target for cancer therapy. Also post-translational modification (PTM) and co-chaperone proteins modulate Hsp90 function, providing additional targets for secondary inhibition. Recent reports have shown that pathogens utilize both their own Hsp90 and that of their host for the propagation of infectious elements. In this review we will summarize our current knowledge of Hsp90 structure and function in both the pathogen and the host. We will focus on the role of Hsp90 in viral and parasitic diseases and the potential beneficial application of Hsp90 inhibitors alone and in combination with disease-specific inhibitors.
Keywords: Heat shock protein 90, Molecular Chaperones, Co-chaperone, Combination therapy, Hsp90, Pathogens, Posttranslational modification.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Targeting Hsp90 in Non-Cancerous Maladies
Volume: 16 Issue: 25
Author(s): Mark R. Woodford, Diana M. Dunn, Joseph G. Ciciarelli, Kristin Beebe, Len Neckers and Mehdi Mollapour
Affiliation:
Keywords: Heat shock protein 90, Molecular Chaperones, Co-chaperone, Combination therapy, Hsp90, Pathogens, Posttranslational modification.
Abstract: Heat shock protein–90 (Hsp90) is a molecular chaperone critical to the folding, stability and activity of over 200 client proteins including many responsible for tumor initiation, progression and metastasis. Hsp90 chaperone function is linked to its ATPase activity and Hsp90 inhibitors interfere with this activity, thereby making Hsp90 an attractive target for cancer therapy. Also post-translational modification (PTM) and co-chaperone proteins modulate Hsp90 function, providing additional targets for secondary inhibition. Recent reports have shown that pathogens utilize both their own Hsp90 and that of their host for the propagation of infectious elements. In this review we will summarize our current knowledge of Hsp90 structure and function in both the pathogen and the host. We will focus on the role of Hsp90 in viral and parasitic diseases and the potential beneficial application of Hsp90 inhibitors alone and in combination with disease-specific inhibitors.
Export Options
About this article
Cite this article as:
Woodford R. Mark, Dunn M. Diana, Ciciarelli G. Joseph, Beebe Kristin, Neckers Len and Mollapour Mehdi, Targeting Hsp90 in Non-Cancerous Maladies, Current Topics in Medicinal Chemistry 2016; 16 (25) . https://dx.doi.org/10.2174/1568026616666160413141753
DOI https://dx.doi.org/10.2174/1568026616666160413141753 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Silico Approach to Inhibition of Tyrosinase by Ascorbic Acid Using Molecular Docking Simulations
Current Topics in Medicinal Chemistry Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Natural Product as Substrates of ABC Transporters: A Review
Recent Patents on Anti-Cancer Drug Discovery Oligonucleotides and Oligonucleotide Conjugates: A New Approach for Cancer Treatment
Current Medicinal Chemistry Ultrasound Assisted Faster and Milder Approach to 6H-pyrido[1,2-a] quinazolin-6-imine Derivatives as Potential Inhibitors of PDE4
Letters in Drug Design & Discovery Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glycolipid Antigen – Mediated Invariant NKT Cell Activation in Microbial Immunity
Current Immunology Reviews (Discontinued) Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Selenium and Cardiovascular Surgery: An Overview
Current Drug Safety Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Current Cancer Drug Targets <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Evaluating Gene Delivery Using N-triethyl Chitosan Nanoparticles to AsPC-1 Cells and Predicting the Relation between Transfection, Cytotoxicity and Charge Ratio of Nanoparticles Via Mathematical Models
Drug Delivery Letters Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry Vitamin D Analogs in Cutaneous Malignancies
Current Pharmaceutical Design Development of Taxol and Other Endophyte Produced Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery